{"id":"NCT02040779","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-12-26","primaryCompletion":"2014-12-24","completion":"2014-12-24","firstPosted":"2014-01-20","resultsPosted":"2017-12-11","lastUpdate":"2021-11-09"},"enrollment":273,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Persistent Asthma"],"interventions":[{"type":"DRUG","name":"Beclomethasone dipropionate breath-actuated inhaler","otherNames":["BDP"]},{"type":"DRUG","name":"Placebo breath-actuated inhaler","otherNames":[]},{"type":"DRUG","name":"albuterol/salbutamol","otherNames":["bronchodilators"]}],"arms":[{"label":"BDP 80 mcg BAI","type":"EXPERIMENTAL"},{"label":"BDP 160 mcg BAI","type":"EXPERIMENTAL"},{"label":"Placebo BAI","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a Breath-Actuated Inhaler (BAI); or a matching BAI placebo, in a 1:1:1 ratio after a 14- to 21-day run-in period. Participants and investigators will remain blinded to randomized treatment assignment during the study","primaryOutcome":{"measure":"Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received","timeFrame":"Baseline (Day 1 predose), weeks 2, 4, 8 and 12","effectByArm":[{"arm":"Placebo BAI","deltaMin":0.048,"sd":0.0252},{"arm":"BDP 80 mcg BAI","deltaMin":0.171,"sd":0.0254},{"arm":"BDP 160 mcg BAI","deltaMin":0.164,"sd":0.0248}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0010"},{"comp":"OG000 vs OG001","p":"0.0005"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":47,"countries":["United States"]},"refs":{"pmids":["28886758"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":91},"commonTop":[]}}